{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:33:35Z","timestamp":1787506415087,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/dad.0000000000000241","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T07:52:53Z","timestamp":1414655573000},"page":"389-397","source":"Crossref","is-referenced-by-count":31,"title":["Clinicopathological Characteristics and Mutation Profiling in Primary Cutaneous Melanoma"],"prefix":"10.1097","volume":"37","author":[{"given":"Banu","family":"Yaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Akalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fen","family":"Kandilo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","article-title":"The role of Kit-ligand in melanocyte development and epidermal homeostasis.","volume":"16","author":"Wehrle-Haller","year":"2003","journal-title":"Pigment Cell Res"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1755-148X.2009.00645.x","article-title":"Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.","volume":"23","author":"Takata","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R3-6-20210202","first-page":"5475","article-title":". The p16-cyclin DCdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.","volume":"56","author":"Bartkova","year":"1996","journal-title":"Cancer Res"},{"key":"R4-6-20210202","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.","volume":"5","author":"Scolyer","year":"2011","journal-title":"Mol Oncol"},{"key":"R5-6-20210202","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":". Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"463184","DOI":"10.1155\/2011\/463184","article-title":"Molecular nevogenesis.","volume":"2011","author":"Ross","year":"2011","journal-title":"Dermatol Res Pract"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":". Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.","volume":"24","author":"Devitt","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":". BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":". Germline p16 mutations in familial melanoma.","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat Genet"},{"key":"R10-6-20210202","first-page":"1968","article-title":". Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.","volume":"60","author":"Bastian","year":"2000","journal-title":"Cancer Res"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1755-148X.2012.00979.x","article-title":"The genetics of uveal melanoma: an emerging framework for targeted therapy.","volume":"25","author":"Harbour","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.humpath.2010.05.027","article-title":". Somatic mutations in GNAQ in amelanotichypomelanotic blue nevi.","volume":"42","author":"Emley","year":"2011","journal-title":"Hum Pathol"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.humpath.2005.03.015","article-title":". Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.","volume":"36","author":"Willmore-Payne","year":"2005","journal-title":"Hum Pathol"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":". NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":". B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.","volume":"2","author":"Ugurel","year":"2007","journal-title":"PLoS One"},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdermsci.2012.03.005","article-title":". Assessment of BRAF and KIT mutations in Japanese melanoma patients.","volume":"66","author":"Ashida","year":"2012","journal-title":"J Dermatol Sci"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":". Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"e35309","DOI":"10.1371\/journal.pone.0035309","article-title":". Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":". Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R20-6-20210202","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":". BRAF inhibitor activity in V600R metastatic melanoma.","volume":"49","author":"Klein","year":"2013","journal-title":"Eur J Cancer"},{"key":"R21-6-20210202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":". Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"R22-6-20210202","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":". Improving melanoma classification by integrating genetic and morphologic features.","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med"},{"key":"R23-6-20210202","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jdermsci.2013.07.013","article-title":". KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.","volume":"72","author":"Zebary","year":"2013","journal-title":"J Dermatol Sci"},{"key":"R24-6-20210202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CMR.0b013e3282f32517","article-title":". Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.","volume":"18","author":"Akslen","year":"2008","journal-title":"Melanoma Res"},{"key":"R25-6-20210202","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","article-title":". Genetic and morphologic features for melanoma classification.","volume":"23","author":"Broekaert","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R26-6-20210202","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000356878","article-title":". Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications.","volume":"86","author":"Richetta","year":"2014","journal-title":"Oncology"},{"key":"R27-6-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/modpathol.2008.41","article-title":". In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.","volume":"21","author":"Venesio","year":"2008","journal-title":"Mod Pathol"},{"key":"R28-6-20210202","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":". Distinct clinical and pathological features are associated with the BRAF (T1799A (V600E)) mutation in primary melanoma.","volume":"127","author":"Liu","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R29-6-20210202","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":". Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.","volume":"12","author":"Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R30-6-20210202","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.0022-202X.2005.23833.x","article-title":"Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.","volume":"125","author":"Lang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R31-6-20210202","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":". Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.","volume":"1","author":"Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"R32-6-20210202","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":". Somatic activation of KIT in distinct subtypes of melanoma.","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R33-6-20210202","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"R34-6-20210202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/PDM.0b013e318298c1d9","article-title":". Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults.","volume":"22","author":"Estrozi","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R35-6-20210202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":". The role of BRAF V600 mutation in melanoma.","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"R36-6-20210202","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.5858\/2007-131-1361-BMIMLA","article-title":". BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.","volume":"131","author":"Hay","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"R37-6-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":". Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J Transl Med"},{"key":"R38-6-20210202","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1158\/1078-0432.CCR-12-2974","article-title":". Clinicopathologic features of V600E and V600K melanomaletter.","volume":"18","author":"Jewell","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R39-6-20210202","first-page":"510","article-title":". Oncogenetics of melanoma: basis for molecular diagnostics and therapy Article in English, German.","volume":"9","author":"Held","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"R40-6-20210202","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/95.11.790","article-title":". Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.","volume":"95","author":"Eskandarpour","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R41-6-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.cmr.0000222600.73179.f3","article-title":". BRAF and NRAS mutations in melanoma and melanocytic nevi.","volume":"16","author":"Poynter","year":"2006","journal-title":"Melanoma Res"},{"key":"R42-6-20210202","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1038\/sj.onc.1206909","article-title":"Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.","volume":"22","author":"Kumar","year":"2003","journal-title":"Oncogene"},{"key":"R43-6-20210202","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2009.109","article-title":". Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.","volume":"22","author":"Lazar","year":"2009","journal-title":"Mod Pathol"},{"key":"R44-6-20210202","first-page":"121","article-title":". ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development.","volume":"5","author":"Shukla","year":"1989","journal-title":"Oncogene Res"},{"key":"R45-6-20210202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.11722","article-title":". Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.","volume":"109","author":"Reifenberger","year":"2004","journal-title":"Int J Cancer"},{"key":"R46-6-20210202","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.humpath.2006.01.003","article-title":". BRAF and c-kit gene copy number in mutation-positive malignant melanoma.","volume":"37","author":"Willmore-Payne","year":"2006","journal-title":"Hum Pathol"},{"key":"R47-6-20210202","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":". KIT gene mutations and copy number in melanoma subtypes.","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R48-6-20210202","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000350683","article-title":". Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with Sinonasal melanoma.","volume":"226","author":"Colombino","year":"2013","journal-title":"Dermatology"},{"key":"R49-6-20210202","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":". Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginousmucosal type.","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"R50-6-20210202","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":". Sunitinib therapy for melanoma patients with KIT mutations.","volume":"18","author":"Minor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R51-6-20210202","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ijc.24048","article-title":". Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.","volume":"124","author":"Ashida","year":"2009","journal-title":"Int J Cancer"},{"key":"R52-6-20210202","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.suc.2008.04.005","article-title":"Familial melanoma.","volume":"88","author":"Hansson","year":"2008","journal-title":"Surg Clin North Am"},{"key":"R53-6-20210202","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/sj.onc.1206445","article-title":"Genetics of melanoma predisposition.","volume":"22","author":"Hayward","year":"2003","journal-title":"Oncogene"},{"key":"R54-6-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/jid.2013.270","article-title":"; Melanoma Genetics Consortium (GenoMEL). Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.","volume":"134","author":"Zebary","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R55-6-20210202","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2012.03.048","article-title":". LKB1STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.","volume":"21","author":"Liu","year":"2012","journal-title":"Cancer Cell"},{"key":"R56-6-20210202","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.2804","article-title":"A new era: melanoma genetics and therapeutics.","volume":"223","author":"Ko","year":"2011","journal-title":"J Pathol"},{"key":"R57-6-20210202","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1038\/sj.onc.1207780","article-title":". BRAF alterations are associated with complex mutational profiles in malignant melanoma.","volume":"23","author":"Daniotti","year":"2004","journal-title":"Oncogene"},{"key":"R58-6-20210202","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":". Genetic interaction between NRAS and BRAF mutations and PTENMMAC1 inactivation in melanoma.","volume":"122","author":"Tsao","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R59-6-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":". Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.","volume":"126","author":"Goel","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:50:57Z","timestamp":1650480657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201505000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000241","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}